SERINC4 Inhibitors
SERINC4 inhibitors are a class of chemical agents that target the SERINC4 (Serine Incorporator 4) protein, which is a member of the serine incorporator family of proteins. These proteins are integral membrane proteins that are involved in the incorporation of serine into membrane lipids, thus playing a role in the biosynthesis of the cell membrane. SERINC4, in particular, has been identified as having a crucial function within the cellular architecture, influencing the biosynthesis and the composition of the lipid membrane. The inhibitors designed to target SERINC4 are specialized molecules that can specifically bind to this protein, affecting its normal function. By doing so, they alter the process of serine incorporation, which can lead to changes in the lipid composition of the cellular membrane.
The study of SERINC4 inhibitors is grounded in the understanding of molecular interactions at the cellular level, especially those that govern the composition and dynamics of cell membranes. The inhibitors work by engaging with the SERINC4 protein in a way that hampers its ability to contribute to lipid biosynthesis. This interaction involves the precise fit between the inhibitor molecule and the SERINC4 protein, often engaging in a lock-and-key mechanism that is typical for enzyme and substrate or enzyme and inhibitor interactions. The chemical structure of these inhibitors is such that they can closely mimic or competitively inhibit the binding of the natural substrates or cofactors of the SERINC4 protein. This precise targeting requires a deep understanding of the protein's structure and the key domains that are responsible for its activity. The development of such inhibitors is a complex process that requires the identification of effective compounds, the assessment of their specificity and selectivity for SERINC4, and an understanding of the molecular pathways that are affected by the inhibition of this protein's activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PF-429242 | 947303-87-9 | sc-507498 | 5 mg | $176.00 | ||
PF-429242 is a potent inhibitor of site-1 protease (S1P), which is necessary for the activation of sterol regulatory element-binding proteins (SREBPs). SREBPs are transcription factors that regulate the synthesis of cholesterol and fatty acids. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
GW4869 is an inhibitor of acid sphingomyelinase (ASM), which catalyzes the hydrolysis of sphingomyelin to ceramide. SERINC4 is thought to play a role in sphingolipid metabolism and membrane dynamics. By inhibiting ASM, GW4869 leads to reduced ceramide production, which can indirectly decrease SERINC4 activity by altering the membrane environment where SERINC4 operates. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 is an inhibitor of NEDD8-activating enzyme, which is essential for the neddylation process that regulates protein function and stability. SERINC4 may be subject to regulation by neddylation. MLN4924, by inhibiting this process, could indirectly decrease SERINC4 stability and function. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
DBeQ is an ATP-competitive inhibitor of p97, an AAA ATPase involved in endoplasmic reticulum-associated degradation (ERAD). SERINC4, as an ER-resident protein, could be affected by the disruption of ERAD. DBeQ, by blocking p97, may lead to an accumulation of misfolded proteins in the ER, indirectly impairing SERINC4 trafficking or function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), critical for vesicular trafficking between the Golgi apparatus and the ER. SERINC4 is involved in serine incorporation during protein synthesis. By inhibiting ARF, Brefeldin A can indirectly affect SERINC4 by disrupting its trafficking and localization within the cell. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, a post-translational modification critical for protein folding and stability. SERINC4 may be glycosylated, and by inhibiting this process, Tunicamycin could indirectly impair SERINC4's proper folding and function. | ||||||
Cerulenin (synthetic) | 17397-89-6 | sc-200827 sc-200827A sc-200827B | 5 mg 10 mg 50 mg | $158.00 $306.00 $1186.00 | 9 | |
Cerulenin is an inhibitor of fatty acid synthase (FAS), responsible for the de novo synthesis of fatty acids. SERINC4's activity is related to membrane dynamics, which are influenced by the fatty acid composition. Inhibition of FAS by Cerulenin could indirectly affect SERINC4's role by altering membrane lipid profiles. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
U18666A is a cholesterol transport inhibitor that can induce intracellular cholesterol accumulation and mimic the genetic disorder Niemann-Pick Type C. SERINC4, which may be involved in cholesterol metabolism and membrane dynamics, could be indirectly inhibited by U18666A through the disruption of normal cholesterol trafficking and membrane composition. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $215.00 $622.00 | 5 | |
Manumycin A is an inhibitor of farnesyltransferase, an enzyme involved in the post-translational modification of proteins via farnesylation. SERINC4 could be indirectly affected by Manumycin A if it is subject to regulation by farnesylation, which would impact its localization and function. | ||||||